Safety and Effectiveness of EV-Pure + WJ-Pure Treatment on Pulmonary Fibrosis Secondary to Covid-19
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The COVID-induced fibrotic lung damage continues long after viral infection has subsided and
is exhibited by severe respiratory pathology and concomitant symptoms. The long-lasting
sequelae in patients who have recovered from severe COVID indicate that there is a 30% chance
of developing a persistent respiratory system pathology and a 10% chance of developing a
severe pathology. The symptoms of lung fibrosis include a severe disruption of respiration,
reduction of exercise tolerance, and concomitant development of persistent fibrotic lung
damage. This study intends to evaluate benefits of a combination of WJPure and EVPure in
Covid-19 patients exhibiting pulmonary fibrosis.